We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+18.29%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$1.87B
AUM Growth
+$330M
Cap. Flow
+$161M
Cap. Flow %
8.59%
Top 10 Hldgs %
73.27%
Holding
30
New
3
Increased
7
Reduced
1
Closed
4

Top Buys

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$51.7M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$50.5M
3
TGTX icon
TG Therapeutics
TGTX
+$44.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$37.3M
5
PGNX
Progenics Pharmaceuticals Inc
PGNX
+$23.3M

Top Sells

Rank Stock Value
1
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$58M
2
CLSD
Clearside Biomedical
CLSD
+$16.3M
3
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$11.4M
4
SPRO icon
Spero Therapeutics
SPRO
+$10.9M
5
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$1.74M

Sector Composition

Rank Sector Weight
1 Healthcare 93.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TARA icon
26
Protara Therapeutics
TARA
$214M
$2.61M 0.14%
33,437
– –
CLSD
27
DELISTED
Clearside Biomedical
CLSD
– –
-101,667
Closed -$16.3M
SPRO icon
28
Spero Therapeutics
SPRO
$68.9M
– –
-741,647
Closed -$10.9M
GTHX
29
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
– –
-40,000
Closed -$1.74M
AVEO
30
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
– –
-506,276
Closed -$11.4M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, RA Capital Management held 30 positions worth $1.87B, up 21% from $1.54B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

RA Capital Management deployed $161M of net new capital in Q3 2018, opening 3 new positions and adding to 7 existing holdings. Its largest new stake was Arvinas: 3,138,412 shares worth $52.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was Momenta Pharmaceuticals, Inc., an estimated $58M trimmed.

  • RA Capital Management's largest Q3 2018 buy was Arvinas: 3,138,412 shares worth $52.9M.
  • RA Capital Management added most to TG Therapeutics in Q3 2018, an estimated $44.8M increase.
  • RA Capital Management's biggest Q3 2018 reduction was Momenta Pharmaceuticals, Inc., cutting an estimated $58M.
  • RA Capital Management fully exited Clearside Biomedical in Q3 2018, selling an estimated $16.3M.
  • RA Capital Management's ten largest holdings make up 73% of its $1.87B portfolio in Q3 2018.
  • RA Capital Management opened 3 new positions and closed 4 in Q3 2018.
  • RA Capital Management's portfolio value rose 21% quarter-over-quarter to $1.87B.

Based on RA Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.